EC
GPCR icon

EntryPoint Capital’s Structure Therapeutics GPCR Stock Holding History

EntryPoint Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
+6,136
New +$271K 0.08% 506
2025
Q1 		– Sell
-13,260
Closed -$360K – 775
2024
Q4 		$360K Buy
13,260
+8,095
+157% +$287K 0.15% 258
2024
Q3 		$227K Buy
5,165
+1,480
+40% +$57.2K 0.13% 386
2024
Q2 		$145K Buy
3,685
+3,467
+1,590% +$142K 0.07% 591
2024
Q1 		$9.34K Sell
218
-7,617
-97% -$321K 0.01% 1245
2023
Q4 		$319K Buy
+7,835
New +$449K 0.31% 18

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

EntryPoint Capital's GPCR Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Structure Therapeutics (GPCR) in Q2 2026: 6,136 shares worth $329K. The stake represents 0.08% of the portfolio and ranks #506 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in GPCR as recently as Q4 2024.

EntryPoint Capital first reported a position in GPCR in Q4 2023 and has held it in 6 quarters since. The position peaked at $360K in Q4 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • EntryPoint Capital held 6,136 shares of Structure Therapeutics worth $329K as of Q2 2026.
  • Structure Therapeutics was a new EntryPoint Capital position in Q2 2026.
  • Structure Therapeutics made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #506 holding.
  • EntryPoint Capital first reported a position in Structure Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • EntryPoint Capital's Structure Therapeutics position peaked at $360K in Q4 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.